Prevention of irreversible disability is currently the most important goal of disease modifying
therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on …

Background: The anticipated rate of short-term worsening of disability scores is the basis of
power estimations in clinical trials of progressive multiple sclerosis (MS). While the clinician …

OBJECTIVES Recent phase III clinical trials of immunomodulatory therapies in relapsing-
remitting multiple sclerosis have shown significant benefits of active treatment on relapse …

It is well documented that disability accumulation in multiple sclerosis is correlated with
axonal injury and that the extent of axonal injury is correlated with the degree of …

Many of the available disability outcome measures used in clinical trials of multiple sclerosis
are insensitive to change over time, inadequately validated, or insensitive to patient …

Importance Clinicians' experience and findings from recent natural history studies suggest
that multiple sclerosis (MS) may now be running a more slowly progressing course than …

Background: In patients with multiple sclerosis (MS), the natural history of the disease is of
considerable importance to predict and understand long-term outcome and inform choices …

Background: There is no consensus method for determining progression of disability in
patients with multiple sclerosis (MS) when each patient has had only a single assessment in …

Objective To identify predictors of 10‐year Expanded Disability Status Scale (EDSS) change
after treatment initiation in patients with relapse‐onset multiple sclerosis. Methods Using …

Clinical assessment of outcome in Multiple Sclerosis (MS) patients is problematic since the
disease can affect different aspects of the central nervous system and follow a variable …